Modulation of LPS-induced pulmonary neutrophil infiltration and cytokine production by the selective PPARβ/δ ligand GW0742

Inflammation Research

Volumn 57, Issue 7, 2008, Pages 314-321

  Haskova, Z ^a   Hoang, B ^a   Luo, G ^a   Morgan, L A ^a   Billin, A N ^a   Barone, F C ^b   Shearer, B G ^a   Barton, M E ^a   Kilgore, K S ^a  

^a GLAXOSMITHKLINE   (United States)

^b GlaxoSmithKline Pharmaceuticals ^*

Author keywords

Cytokines; Inflammation; Lipopolysaccharide induced inflammation; Neutrophilia; PPAR activators; PPAR agonism; Pulmonary injury

Indexed keywords

[4 [2 (3 FLUORO 4 TRIFLUOROMETHYLPHENYL) 4 METHYL 5 THIAZOLYLMETHYLTHIO] 2 METHYLPHENOXY]ACETIC ACID; CHEMOKINE; CYTOKINE; DEXAMETHASONE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PROTEIN KC; PROTEIN MIP 2ALPHA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG ACTIVITY; DRUG DOSE INCREASE; DRUG EFFECT; DRUG STRUCTURE; HISTOPATHOLOGY; IN VIVO STUDY; LEUKOCYTE; LUNG LAVAGE; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PROTEIN BLOOD LEVEL; RNA ANALYSIS;

ANIMALS; CYTOKINES; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; INFLAMMATION; LEUKOCYTES; LIGANDS; LIPOPOLYSACCHARIDES; MALE; MICE; MICE, INBRED BALB C; MODELS, BIOLOGICAL; NEUTROPHILS; PPAR DELTA; PPAR-BETA; THIAZOLES;

EID: 51849149335     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-007-7157-4     Document Type: Article

References (37)

1. Willson TM, Brown PJ, Sternbach DD, Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000; 43: 527-50.
2. Desvergne B, Wahli W: Peroxisome proliferator-activated receptors: nuclear control of metabolism. Endocr Rev 1999; 20: 649-88.
3. Bocher V, Pineda-Torra I, Fruchart JC, Staels B: PPARs: transcription factors controlling lipid and lipoprotein metabolism. Ann N Y Acad Sci 2002; 967: 7-18.
4. Sharma AM, Staels B: Review: Peroxisome proliferator-activated receptor gamma and adipose tissue - understanding obesity-related changes in regulation of lipid and glucose metabolism. J Clin Endocrinol Metab 2007; 92: 386-95.
5. Higashiyama H, Billin AN, Okamoto Y, Kinoshita M, Asano S: Expression profiling of Peroxisome proliferator-activated receptor-delta (PPAR-delta) in mouse tissues using tissue microarray. Histochem Cell Biol 2007; 127: 485-94.
6. Hansen JB, Zhang H, Rasmussen TH, Petersen RK, Flindt EN, Kristiansen K: Peroxisome proliferator-activated receptor delta (PPARdelta )-mediated regulation of preadipocyte proliferation and gene expression is dependent on cAMP signaling. J Biol Chem 2001; 276: 3175-82.
7. Saluja I, Granneman JG, Skoff RP: PPAR delta agonists stimulate oligodendrocyte differentiation in tissue culture. Glia 2001; 33: 191-204.
8. Oliver WR, Jr., Shenk JL, Snaith MR, Russell CS, Plunket KD, Bodkin NL, Lewis MC, Winegar DA, Sznaidman ML, Lambert MH, Xu HE, Sternbach DD, Kliewer SA, Hansen BC, Willson TM: A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport. Proc Natl Acad Sci U S A 2001; 98: 5306-11.
9. Denning GM, Stoll LL: Peroxisome proliferator-activated receptors: potential therapeutic targets in lung disease? Pediatr Pulmonol 2006; 41: 23-34.
10. Kostadinova R, Wahli W, Michalik L: PPARs in diseases: control mechanisms of inflammation. Curr Med Chem 2005; 12: 2995-3009.
11. Becker J, Delayre-Orthez C, Frossard N, Pons F: Regulation of inflammation by PPARs: a future approach to treat lung inflammatory diseases? Fundam Clin Pharmacol 2006; 20: 429-47.
12. Berger J, Moller DE: The mechanisms of action of PPARs. Annu Rev Med 2002; 53: 409-35.
13. Glass CK, Ogawa S: Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006; 6: 44-55.
14. Ding G, Cheng L, Qin Q, Frontin S, Yang Q: PPARdelta modulates lipopolysaccharide-induced TNFalpha inflammation signaling in cultured cardiomyocytes. J Mol Cell Cardiol 2006; 40: 821-8.
15. Planavila A, Laguna JC, Vazquez-Carrera M: Nuclear factor-kappaB activation leads to down-regulation of fatty acid oxidation during cardiac hypertrophy. J Biol Chem 2005; 280: 17464-71.
16. Rival Y, Beneteau N, Taillandier T, Pezet M, Dupont-Passelaigue E, Patoiseau JF, Junquero D, Colpaert FC, Delhon A: PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells. Eur J Pharmacol 2002; 435: 143-51.
17. Tan NS, Michalik L, Noy N, Yasmin R, Pacot C, Heim M, Fluhmann B, Desvergne B, Wahli W: Critical roles of PPAR beta/delta in keratinocyte response to inflammation. Genes Dev 2001; 15: 3263-77.
18. Westergaard M, Henningsen J, Johansen C, Rasmussen S, Svendsen ML, Jensen UB, Schroder HD, Staels B, Iversen L, Bolund L, Kragballe K, Kristiansen K: Expression and localization of peroxisome proliferator-activated receptors and nuclear factor kappaB in normal and lesional psoriatic skin. J Invest Dermatol 2003; 121: 1104-17.
19. Graham TL, Mookherjee C, Suckling KE, Palmer CN, Patel L: The PPARdelta agonist GW0742X reduces atherosclerosis in LDLR(-/-) mice. Atherosclerosis 2005; 181: 29-37.
20. Schmuth M, Haqq CM, Cairns WJ, Holder JC, Dorsam S, Chang S, Lau P, Fowler AJ, Chuang G, Moser AH, Brown BE, Mao-Qiang M, Uchida Y, Schoonjans K, Auwerx J, Chambon P, Willson TM, Elias PM, Feingold KR: Peroxisome proliferator-activated receptor (PPAR)-beta/delta stimulates differentiation and lipid accumulation in keratinocytes. J Invest Dermatol 2004; 122: 971-83.
21. Hollingshead HE, Morimura K, Adachi M, Kennett MJ, Billin AN, Willson TM, Gonzalez FJ, Peters JM: PPARbeta/delta Protects Against Experimental Colitis Through a Ligand-Independent Mechanism. Dig Dis Sci 2007.
22. Trifilieff A, Bench A, Hanley M, Bayley D, Campbell E, Whittaker P: PPAR-alpha and -gamma but not -delta agonists inhibit airway inflammation in a murine model of asthma: in vitro evidence for an NF-kappaB-independent effect. Br J Pharmacol 2003; 139: 163-71.
23. Knapp S, Florquin S, Golenbock DT, van der PT: Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol 2006; 176: 3189-95.
24. Jablonska E: Effect of soluble interleukin-6 receptor alpha and interleukin-6 secreted by polymorphonuclear leukocytes on tumor necrosis factor-alpha expression and its production by peripheral blood mononuclear cells. Mediators Inflamm 2002; 11: 325-8.
25. Jeyaseelan S, Chu HW, Young SK, Worthen GS: Transcriptional profiling of lipopolysaccharide-induced acute lung injury. Infect Immun 2004; 72: 7247-56.
26. Huang S, Paulauskis JD, Godleski JJ, Kobzik L: Expression of macrophage inflammatory protein-2 and KC mRNA in pulmonary inflammation. Am J Pathol 1992; 141: 981-8.
27. Schmal H, Shanley TP, Jones ML, Friedl HP, Ward PA: Role for macrophage inflammatory protein-2 in lipopolysaccharide-induced lung injury in rats. J Immunol 1996; 156: 1963-72.
28. Gomez-Cambronero J, Horn J, Paul CC, Baumann MA: Granulocyte-macrophage colony-stimulating factor is a chemoattractant cytokine for human neutrophils: involvement of the ribosomal p70 S6 kinase signaling pathway. J Immunol 2003; 171: 6846-55.
29. Vlahos R, Bozinovski S, Hamilton JA, Anderson GP: Therapeutic potential of treating chronic obstructive pulmonary disease (COPD) by neutralising granulocyte macrophage-colony stimulating factor (GM-CSF). Pharmacol Ther 2006; 112: 106-15.
30. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, McDonald R, Phare SM, Peters-Golden M, Paine R, III, Toews GB: GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol 2000; 165: 4032-9.
31. Bozinovski S, Jones JE, Vlahos R, Hamilton JA, Anderson GP: Granulocyte/macrophage-colony-stimulating factor (GM-CSF) regulates lung innate immunity to lipopolysaccharide through Akt/Erk activation of NFkappa B and AP-1 in vivo. J Biol Chem 2002; 277: 42808-14.
32. Puljic R, Benediktus E, Plater-Zyberk C, Baeuerle PA, Szelenyi S, Brune K, Pahl A: Lipopolysaccharide-induced lung inflammation is inhibited by neutralization of GM-CSF. Eur J Pharmacol 2007; 557: 230-5.
33. Paola RD, Cuzzocrea S: Peroxisome proliferator-activated receptors and acute lung injury. PPAR Res 2007; 2007: 63745.
34. Delayre-Orthez C, Becker J, Guenon I, Lagente V, Auwerx J, Frossard N, Pons F: PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir Res 2005; 6: 91.
35. Liu D, Zeng BX, Zhang SH, Yao SL: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces pulmonary inflammatory response in a rat model of endotoxemia. Inflamm Res 2005; 54: 464-70.
36. Genovese T, Cuzzocrea S, Di Paola R, Mazzon E, Mastruzzo C, Catalano P, Sortino M, Crimi N, Caputi AP, Thiemermann C, Vancheri C: Effect of rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2 on bleomycin-induced lung injury. Eur Respir J 2005; 25: 225-34.
37. Birrell MA, Patel HJ, McCluskie K, Wong S, Leonard T, Yacoub MH, Belvisi MG: PPAR-gamma agonists as therapy for diseases involving airway neutrophilia. Eur Respir J 2004; 24: 18-23.